Adjuvant therapies after surgery for hepatocellular carcinoma with microvascular invasion
DOI:10.3969/j.issn.1001-5256.2021.03.037
- VernacularTitle:肝细胞癌微血管侵犯的术后辅助治疗
- Author:
Tianle GONG
1
;
Ping YUE
;
Jun YAN
;
Xun LI
Author Information
1. The First Clinical Medical College, Lanzhou University, Lanzhou 730000, China
- Publication Type:Research Article
- Keywords:
Carcinoma, Hepatocellular;
Microvascular Invasion;
Neoadjuvant Therapy
- From:
Journal of Clinical Hepatology
2021;37(3):685-689
- CountryChina
- Language:Chinese
-
Abstract:
The high recurrence rate of hepatocellular carcinoma (HCC) after surgery cannot be ignored, but there are still no consensus statements and guideline recommendations for adjuvant therapies after HCC surgery. Current studies have shown that microvascular invasion is one of the high-risk factors for postoperative recurrence of HCC, and for HCC patients with microvascular invasion, timely postoperative adjuvant therapy may delay the time to recurrence and bring benefits to patients. At this stage, the prevention of postoperative recurrence of HCC and the prolongation of survival time through adjuvant therapy have attracted more and more attention. This article reviews the research advances in adjuvant therapy after surgery for HCC with microvascular invasion in recent years, in order to provide reference and help for postoperative adjuvant therapies for HCC patients with microvascular invasion.
